A panel of eminent researchers sit down and construct a list of seven grand cancer challenges. Of course one challenge is to design a drug that will block MYC, the 'undruggable' target.
To be truly grand the task must be ambitious but not impossible. Richard Klausner, chair of the CRUK challenge-selection committee said that the challenges have been set at the edge of doable.
It would appear that Phylogica is working on the edge of doable with some worthwhile results-to-date. Whether, it lodges an application for the Grand Challenge itself, is unknown. What is known, however, is its strategy in defining an externally facilitated process which somewhat coincidentally replicates the team approach favoured in the Grand Challenge model.
CRUK has very successfully shone the spotlight on MYC. The research by Phylogica will be watched with great interest and early success will not go unnoticed.
PYC Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)